Tests AZD5492 antibody in adults with returning or resistant B-cell blood cancers
Tests AZD5492 in adults with B-cell blood cancers that returned.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
Key facts
- Where
- Göttingen, München, Ulm, and Würzburg, GermanySee the 4 sites
- Phase
- Phase 1/2
Where in Germany
- GöttingenGöttingen, GermanyTaking people
- MünchenMünchen, GermanyTaking people
- UlmUlm, GermanyTaking people
- WürzburgWürzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT06542250
- Record updated
- 30 September 2026
- Original description
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.Read full original descriptionShow less
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With Relapsed or Refractory B-Cell Malignancies (TITANium)
This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
Inclusion: ≥18 years of age; Histologically documented CD20+ mature B-cell neoplasm; Large B-cell lymphoma; Follicular lymphoma; Mantle cell lymphoma; Chronic lymphocytic leukemia; Small lymphocytic lymphoma; Relapsed, progressive and/or refractory disease following at least 2 prior lines of therapy; ECOG performance status of ≤ 2 (< 2 in EU countries); The above is a summary, other inclusion criteria details may apply.
Exclusion: Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy; Unresolved AEs ≥2 Grade due to prior anticancer therapies, with some exceptions; The above is a summary, other exclusion criteria details may apply; CNS pathology including but not limited to any history of seizure disorder/epilepsy; History of Grade ≥ 3 CRS or Grade ≥ 3 ICANS; Active and uncontrolled infections; Any neoplasm histology not specified in the IC section; Active CNS involvement in lymphoma.